Show simple item record

dc.contributor.advisorSawicki, Grzegorzen_US
dc.creatorde Jesus Cadete, Virgilioen_US
dc.date.accessioned2013-01-03T22:32:10Z
dc.date.available2013-01-03T22:32:10Z
dc.date.created2012-08en_US
dc.date.issued2012-09-04en_US
dc.date.submittedAugust 2012en_US
dc.identifier.urihttp://hdl.handle.net/10388/ETD-2012-08-555en_US
dc.description.abstractHeart disease, often results in the development of ischemia/reperfusion (I/R) injury, and is one of the major causes of morbidity and mortality. I/R injury is usually characterized by the development of cardiac contractile dysfunction, which is one of the major indicators of recovery. The understanding of the mechanisms underlying the development cardiac contractile dysfunction in response to I/R is crucial for the prevention and treatment of I/R injury. Using a proteomics approach to an isolated heart model we identified myosin light chain 1 (MLC1) as an important contractile protein, phosphorylated by myosin light chain kinase (MLCK) and degraded by matrix metalloproteinase-2 (MMP-2) due to I/R. Prevention of MLC1 phosphorylation, with an MLCK inhibitor (ML-7) or a myosin light chain phosphatase – MLCP – stimulator (Y-27632), and degradation with an MMPs inhibitor (doxycycline) protects the heart from contractile dysfunction, associated with a preservation of MLC1 protein levels. The combined use of these three drugs (ML-7, Y-27632 and doxycycline) at subthreshold concentrations resulted in a full protection of both contractile function and MLC1 in hearts subjected to I/R. The MLCP indirect activator Y-27632 (a Rho kinase inhibitor) showed the best degree of protection of contractile function at full protective doses, independent of MLC1 preservation. A proteomics approach revealed that the administration of Y-27632 to hearts subjected to I/R results, not only in a protection of MLC1 from phosphorylation and degradation, but also a modulation of enzymes involved in energy production (lactate dehydrogenase and glyceraldehyde 3-phosphate dehydrogenase). This modulation of energy metabolism is potentially an importa effect of Rho kinase inhibitors, secondary to direct protection of cardiac contractile proteins from degradation in response to I/R. The data presented here show a novel paradigm in the development of I/R-induced cardiac contractile dysfunction. Moreover, we establish a new therapeutic approach (multidrug treatment) that can be of crucial importance in the development of new preventive or treatment strategies against cardiac injury.en_US
dc.language.isoengen_US
dc.subjectischemia/reperfusion injuryen_US
dc.subjectmyosin light chain 1en_US
dc.subjectmatrix metalloproteinase-2, cardioprotectionen_US
dc.subjectsynergyen_US
dc.subjectposttranslational modificationsen_US
dc.subjectphosphorylationen_US
dc.subjectY-27632en_US
dc.titleIschemia/reperfusion-induced changes in cardiac contractile proteinsen_US
thesis.degree.departmentPharmacologyen_US
thesis.degree.disciplinePharmacologyen_US
thesis.degree.grantorUniversity of Saskatchewanen_US
thesis.degree.levelDoctoralen_US
thesis.degree.nameDoctor of Philosophy (Ph.D.)en_US
dc.type.materialtexten_US
dc.type.genreThesisen_US
dc.contributor.committeeMemberDesai, Kaushiken_US
dc.contributor.committeeMemberRichardson, J Stevenen_US
dc.contributor.committeeMemberGopalakrishnan, Venkaten_US
dc.contributor.committeeMemberGrochulski, Pawelen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record